Detailed Information on Publication Record
2023
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
VALENT, Peter, Karin HARTMANN, Patrizia BONADONNA, Wolfgang SPERR, Marek NIEDOSZYTKO et. al.Basic information
Original name
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
Authors
VALENT, Peter, Karin HARTMANN, Patrizia BONADONNA, Wolfgang SPERR, Marek NIEDOSZYTKO, Hanneke C KLUIN-NELEMANS, Olivier HERMINE, Karl SOTLAR, Gregor HOERMANN, Boguslaw NEDOSZYTKO, Sigurd BROESBY-OLSEN, Roberta ZANOTTI, Magdalena LANGE, Michael DOUBEK (203 Czech Republic, belonging to the institution), Knut BROCKOW, Ivan ALVAREZ-TWOSE, Judit VARKONYI, Selim YAVUZ, Gunnar NILSSON, Deepti RADIA, Clive GRATTAN, Juliana SCHWAAB, Theo GILLEN, Hanneke N G Oude ELBERINK, Hans HAEGGLUND, Frank SIEBENHAAR, Emir HADZIJUSUFOVIC, Vito SABATO, Jiří MAYER (203 Czech Republic, belonging to the institution), Andreas REITER, Alberto ORFAO, Hans-Peter HORNY, Massimo TRIGGIANI and Michel AROCK
Edition
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, AMSTERDAM, ELSEVIER, 2023, 2213-2198
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30205 Hematology
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 9.400 in 2022
RIV identification code
RIV/00216224:14110/23:00131385
Organization unit
Faculty of Medicine
UT WoS
001023706800001
Keywords in English
Mast cells; Mastocytosis; Mast cell activation dis-orders; MCAS; ECNM
Tags
International impact, Reviewed
Změněno: 9/8/2023 09:24, Mgr. Tereza Miškechová
Abstract
V originále
In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to timely distribute all available information about the disease to patients, doctors, and scientists. In the past 20 years, the ECNM has expanded substantially and contributed successfully to the development of new diagnostic concepts, and to the classification, prognostication, and treatments of patients with mastocytosis and MC activation disorders. The ECNM also organized annual meetings and several working conferences, thereby supporting the license (http://creativecommons.org/licenses/by/4.0/). (J Al-Clin Immunol Pract 2023;11:1706-17)